MY ACCOUNT | NEWSLETTER |

A 12-year retrospective study of canine testicular tumors


To provide up-to-date information on the incidence and risk factors of canine testicular tumors, 476 pathological reports of male canine tumors from two institutes of veterinary medicine in Taiwan over a period of 12 years were reviewed.

The detection rate of testicular tumors was 16.8% (80/476) in male canine tumors, and 94.1% (80/85) in male genital tumors. Ninety-six testicular tumors from 80 dogs were identified in this study, including 33 (34.4%) seminomas (SEMs), 25 (26%) interstitial cell tumors (ICTs), 22 (22.9%) mixed germ cell-stromal cell tumors (MGCSCTs), and 16 (16.6%) Sertoli cell tumors (SCTs). Of the 96 testicular tumors, 52 (54.2%) tumors developed from cryptorchid testes in 45 dogs (56.3%), and 44 (45.8%) tumors developed from scrotal testes in 35 dogs (44.7%).

Cryptorchidism was significantly associated with development of MGCSCTs, SCTs, and SEMs, but not ICTs (p<0.01). The detection rate of testicular tumors in the dog younger than 10-years-old was significantly associated with cryptorchidism (p<0.01). Except for mixed breed dogs, the Maltese breed had high detection rate of testicular tumors, and may have high risk in cryptorchidism in this study.

In conclusion, our results indicate that cryptorchidism alone or in addition to age will significantly affect the incidence and type of canine testicular tumors, and a high detection rate of testicular tumors in Maltese dogs is documented for the first time.


Authors: Albert Taiching LIAO, Pei-Yi CHU, Lih-Sen YEH, Chung-Tien LIN, Chen-Hsuan LIU

Source: https://www.jstage.jst.go.jp/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Like0
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top